Can a 75-year-old woman with Barrett’s esophagus safely continue oral bisphosphonate therapy (Fosamax (alendronate) 70 mg weekly)?

Oral Bisphosphonates Should Be Used With Caution in Barrett's Esophagus

A 75-year-old woman with Barrett's esophagus can continue Fosamax (alendronate) 70 mg weekly, but this requires careful consideration of the risk-benefit balance, as oral bisphosphonates should be used with caution in patients with active esophageal disease.

Key Considerations from FDA Labeling and Guidelines

The FDA label for Fosamax explicitly states that oral bisphosphonates should be used with caution in patients with active esophageal disease, including Barrett's esophagus 1. This is because bisphosphonates can cause local irritation of the upper gastrointestinal mucosa, potentially leading to esophagitis, esophageal ulcers, and erosions 1.

The 2020 AACE/ACE osteoporosis guidelines reinforce this, listing active esophageal disease as a contraindication requiring caution for oral bisphosphonate use 2. Specific contraindications include anatomic or functional esophageal abnormalities that might delay tablet transit (such as stricture, achalasia, or dysmotility) 2.

Barrett's Esophagus as a Definite Indication for PPI Therapy

Importantly, the 2022 AGA guideline on PPI de-prescribing classifies Barrett's esophagus as a definite indication for long-term PPI use 3. The guideline explicitly states that patients with known Barrett's esophagus should generally not be considered for PPI discontinuation because PPIs reduce the risk of progression to esophageal adenocarcinoma 3. This is critical context: if this patient is on adequate PPI therapy for her Barrett's esophagus, this may provide some gastroprotection.

Risk Assessment and Alternative Options

If Continuing Oral Bisphosphonates:

• Ensure strict adherence to dosing instructions: Take with a full glass of water (6-8 oz) upon arising, remain upright for at least 30 minutes, and take before any food or other medications 1
• Maintain adequate PPI therapy for Barrett's esophagus management 3
• Monitor closely for warning symptoms: dysphagia, odynophagia, retrosternal pain, or new/worsening heartburn should prompt immediate discontinuation 1
• Consider the delayed-release risedronate formulation (Atelvia), which may be better tolerated in patients with upper GI problems, though evidence for superior safety is limited 2

Alternative Treatment Options (in order of preference per guidelines):

If oral bisphosphonates are deemed inappropriate 2, 4, 5:

1. IV zoledronic acid (5 mg annually): Bypasses esophageal exposure entirely, though carries higher procedural risk 2, 4, 5
2. Denosumab (60 mg subcutaneously every 6 months): No esophageal exposure, though requires transition to bisphosphonate after completion 2, 6
3. Teriparatide: For very high fracture risk patients, though costly and requires daily injections 2, 4, 5

Evidence on Safety

Research evidence is somewhat reassuring but limited. A 2010 VA study found no increased risk of esophageal adenocarcinoma in Barrett's patients taking oral bisphosphonates 7. A 2020 meta-analysis showed no increased risk of severe GI adverse events with bisphosphonates overall 8, though this excluded patients with pre-existing esophageal disease from most trials.

However, case reports from 1996 documented severe esophagitis with alendronate, particularly when dosing instructions were not followed 9. The FDA label acknowledges post-marketing reports of esophageal adverse events, some severe requiring hospitalization 1.

Clinical Decision Algorithm

For this 75-year-old woman:

1. Assess Barrett's esophagus severity: If she has complicated features (stricture, severe dysplasia, prior ulceration), strongly consider switching to IV bisphosphonate or denosumab
2. Verify PPI adherence: Ensure she's on appropriate PPI therapy for Barrett's esophagus 3
3. Evaluate bisphosphonate adherence history: If she cannot reliably follow strict dosing instructions (upright for 30 minutes, full glass of water, empty stomach), switch to IV zoledronic acid 1
4. Consider fracture risk: At age 75 with osteoporosis indication, her fracture risk likely justifies continued treatment 2, 10
5. If continuing oral therapy: Provide explicit written instructions, ensure understanding of warning symptoms, and schedule close follow-up

Common Pitfalls to Avoid

• Do not assume all Barrett's patients are the same: Uncomplicated Barrett's without stricture or severe dysplasia carries different risk than complicated disease
• Do not continue oral bisphosphonates if warning symptoms develop: This significantly increases risk of severe complications 1
• Do not forget that age 75 may warrant discussion of surveillance discontinuation for Barrett's esophagus itself if life expectancy is limited 11, though this doesn't affect the bisphosphonate decision
• Do not use oral bisphosphonates if the patient cannot follow dosing instructions due to cognitive impairment or physical limitations 1

The safest approach for most patients with Barrett's esophagus requiring bisphosphonate therapy is to switch to IV zoledronic acid annually, which eliminates esophageal exposure while maintaining fracture prevention efficacy 2, 6.